GlassScriptPhysician profile
Keali Mullins
NPI 1790320463
$4,066.34
in general payments reported to CMS, 2019-2025
42 companies · $96.23 in 2025
The $96.23 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,388 · 2022: $886 · 2023: $1,045 · 2024: $651 · 2025: $96.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.41 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.69 | 2021-2024 | |
| Pfizer INC. | $497.26 | 2021-2024 | |
| Novo Nordisk INC | $335.52 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $221.99 | 2021-2024 | Farxiga |
| Abbott Laboratories | $203.20 | 2021-2024 | Freestyle Libre, Infinity |
| Lilly USA, LLC | $193.43 | 2021-2023 | Mounjaro |
| Biohaven Pharmaceuticals, INC. | $169.81 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $157.59 | 2021-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.56 | 2021-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $123.23 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $105.86 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $103.58 | 2022 | |
| Amarin Pharma, INC. | $99.94 | 2021 | |
| Glaxosmithkline, LLC. | $98.35 | 2021-2023 | Shingrix |
| Eisai INC. | $82.45 | 2021-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $81.40 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $74.38 | 2021 | |
| Esperion Therapeutics, INC. | $67.86 | 2021-2023 | Nexletol |
| Exact Sciences Corporation | $65.24 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $64.79 | 2021-2023 | Veozah |
| Shield Therapeutics INC | $58.90 | 2022-2024 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $44.98 | 2021-2023 | Trintellix |
| Dexcom, INC. | $41.84 | 2021-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $36.38 | 2022-2023 | Gvoke Hypopen |
| Upsher-Smith Laboratories LLC | $36.07 | 2022 | |
| Lundbeck LLC | $34.02 | 2022-2023 | Rexulti |
| Sumitomo Pharma America, INC. | $29.82 | 2025 | Gemtesa |
| Organon LLC | $27.77 | 2025 | Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.51 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $24.83 | 2024 | Fanapt |
| Inspire Medical Systems, INC. | $23.34 | 2025 | Inspire |
| Amgen INC. | $22.37 | 2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $21.81 | 2021 | |
| Tris Pharma INC | $20.08 | 2023 | Dyanavel Xr |
| Insulet Corporation | $19.05 | 2021 | |
| Phadia US INC. | $18.23 | 2023 | Immunocap |
| Corcept Therapeutics | $18.06 | 2021 | |
| Boston Scientific Corporation | $16.30 | 2023 | Wavewriter Alpha Prime 16 |
| Biogen, INC. | $15.75 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.07 | 2024 | Eliquis |
| Nestle Healthcare Nutrition INC. | $14.00 | 2022 | |
| Genentech USA, INC. | $3.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keali Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.